[目的]探讨黄连-升麻药对治疗复发性口腔溃疡(recurrent aphthous ulcer,RAU)的现代药理机制,分析可能存在的中医治法相关疗效因素,进一步指导中医临床辨治。[方法]使用中药系统药理学数据库与分析平台(Traditional Chinese Medicine Sy...[目的]探讨黄连-升麻药对治疗复发性口腔溃疡(recurrent aphthous ulcer,RAU)的现代药理机制,分析可能存在的中医治法相关疗效因素,进一步指导中医临床辨治。[方法]使用中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)检索药物成分及靶点,通过在线人类孟德尔遗传(Online Mendelian Inheritance in Man,OMIM)数据库、人类基因组注释数据库(Human Genome Annotation Database,GeneCards)等检索疾病相关靶点,取交集后采用STRING平台进行蛋白互作(protein-protein interaction,PPI)分析,以CytoScape 3.7.2软件绘制PPI网络图并筛选出核心靶点,上传至MetaScape数据库,进行基因本体(gene ontology,GO)富集分析与京都基因和基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)信号通路富集分析并构建网络图,利用AutoDock 4.2.6软件进行分子对接,并采用PyMOL软件将对接结果可视化。采用脊柱两侧注射完全弗氏佐剂的方法构建RAU大鼠模型;采用实时定量聚合酶链式反应(Real-time quantitative polymerase chain reaction,Real-time qPCR)检测各组大鼠口腔组织中核心靶基因的表达情况。[结果]筛选得到黄连、升麻活性成分共19个,靶点191个,药物与疾病交集靶点127个,药对干预RAU核心靶点23个,并依据连接度筛选出7个最关键的靶点,核心通路为白细胞介素-17(interleukin-17,IL-17)与肿瘤坏死因子(tumor necrosis factor,TNF)相关的信号通路。分子对接结果显示核心有效成分豆甾醇与各关键靶点均有较高的结合活性。动物实验发现,该药对可有效减少大鼠口腔溃疡数目。与空白对照组比较,模型组、低剂量组、中剂量组和高剂量组关键靶点表达明显更高(P<0.05);高剂量组靶点的mRNA相对表达和口腔溃疡数明显低于模型组、低剂量组、中剂量组(P<0.05)。[结论]黄连-升麻药对治疗RAU的分子机制,与其抗炎、保护口腔黏膜、调节免疫等作用有关,而相关的中医疗效机制涉及清热解毒、化瘀通络、托毒敛疮生肌等。展开更多
In the market of botanical dietary supplements, Cimicifuga heracleifolia(CH) has always been considered as an adulterated species of Cimicifuga racemosa(CR), a conventional American herb with promising benefits to cou...In the market of botanical dietary supplements, Cimicifuga heracleifolia(CH) has always been considered as an adulterated species of Cimicifuga racemosa(CR), a conventional American herb with promising benefits to counteract troubles arising from the menopause. However, the detailed comparison of their therapeutic effects is lacking. In present study, the pharmacological and metabolomics studies were comparatively conducted between CH and CR in ovariectomized(OVX) female rats. Specifically, estrogen-like, anti-hyperlipidemia and anti-osteoporosis effects were evaluated through measuring serum biochemical parameters, histopathological examination and micro computed tomography(Micro-CT) scanning. At the same time, a gas chromatography-mass spectrometry(GC-MS)-based serum metabolomics method was employed to profile the metabolite compositional changes. As a result, both CR and CH displayed anti-osteoporosis and anti-hyperlipemia on menopause syndrome. Meanwhile, their potentials in improving the OVX-induced metabolic disorders were discovered. In conclusion, these results demonstrated that CH is therapeutically similar to CR in relieving menopausal symptoms and CH could be considered as a promising alternative to CR instead of an adulterant in the market of botanical dietary supplements.展开更多
目的研究小儿升麻方对流感病毒性肺炎小鼠的治疗作用,并通过网络药理学方法探究其抗流感病毒性肺炎的作用机制。方法小鼠随机分为对照组,模型组,小儿升麻方低、中、高剂量(1.75、3.50、7.00g/kg)组和生理盐水组,给药第2天,经鼻滴入0.03 ...目的研究小儿升麻方对流感病毒性肺炎小鼠的治疗作用,并通过网络药理学方法探究其抗流感病毒性肺炎的作用机制。方法小鼠随机分为对照组,模型组,小儿升麻方低、中、高剂量(1.75、3.50、7.00g/kg)组和生理盐水组,给药第2天,经鼻滴入0.03 m L FM1流感病毒尿囊液建立流感病毒性肺炎模型,第7天测定小鼠肺指数。采用网络药理学方法在TCMIP数据库查找小儿升麻方各药材化学成分和靶点信息,在Genecards数据库中查找流感病毒性肺炎相关靶点,通过韦恩图筛选小儿升麻方与流感病毒性肺炎的共同靶点,借助Omicsbean分析系统与STRING数据库对共同靶点进行基因本体(gene ontology,GO)功能富集分析和京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)信号通路分析。结合STRING数据库与Cytoscape 3.7.0软件将共同靶点进行可视化处理,筛选核心靶点,构建"药材-成分-靶点-通路"网络。结果小儿升麻方高剂量组显著降低流感病毒性肺炎小鼠的肺指数(P<0.05)。小儿升麻方与流感病毒性肺炎有69个共同靶点,通过蛋白相互作用(protein-protein interaction,PPI)网络筛选出24个核心靶点,对应29个化学成分,86条主要通路。结论小儿升麻方对流感病毒性肺炎小鼠有潜在的治疗作用,可通过多成分、多靶点、多通路发挥治疗流感病毒性肺炎作用。展开更多
文摘[目的]探讨黄连-升麻药对治疗复发性口腔溃疡(recurrent aphthous ulcer,RAU)的现代药理机制,分析可能存在的中医治法相关疗效因素,进一步指导中医临床辨治。[方法]使用中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)检索药物成分及靶点,通过在线人类孟德尔遗传(Online Mendelian Inheritance in Man,OMIM)数据库、人类基因组注释数据库(Human Genome Annotation Database,GeneCards)等检索疾病相关靶点,取交集后采用STRING平台进行蛋白互作(protein-protein interaction,PPI)分析,以CytoScape 3.7.2软件绘制PPI网络图并筛选出核心靶点,上传至MetaScape数据库,进行基因本体(gene ontology,GO)富集分析与京都基因和基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)信号通路富集分析并构建网络图,利用AutoDock 4.2.6软件进行分子对接,并采用PyMOL软件将对接结果可视化。采用脊柱两侧注射完全弗氏佐剂的方法构建RAU大鼠模型;采用实时定量聚合酶链式反应(Real-time quantitative polymerase chain reaction,Real-time qPCR)检测各组大鼠口腔组织中核心靶基因的表达情况。[结果]筛选得到黄连、升麻活性成分共19个,靶点191个,药物与疾病交集靶点127个,药对干预RAU核心靶点23个,并依据连接度筛选出7个最关键的靶点,核心通路为白细胞介素-17(interleukin-17,IL-17)与肿瘤坏死因子(tumor necrosis factor,TNF)相关的信号通路。分子对接结果显示核心有效成分豆甾醇与各关键靶点均有较高的结合活性。动物实验发现,该药对可有效减少大鼠口腔溃疡数目。与空白对照组比较,模型组、低剂量组、中剂量组和高剂量组关键靶点表达明显更高(P<0.05);高剂量组靶点的mRNA相对表达和口腔溃疡数明显低于模型组、低剂量组、中剂量组(P<0.05)。[结论]黄连-升麻药对治疗RAU的分子机制,与其抗炎、保护口腔黏膜、调节免疫等作用有关,而相关的中医疗效机制涉及清热解毒、化瘀通络、托毒敛疮生肌等。
基金supported by the National Natural Science Foundation of China(Nos.81773993 and 81130068)the National Key R&D Program of China(No.2018YFC-1707905)
文摘In the market of botanical dietary supplements, Cimicifuga heracleifolia(CH) has always been considered as an adulterated species of Cimicifuga racemosa(CR), a conventional American herb with promising benefits to counteract troubles arising from the menopause. However, the detailed comparison of their therapeutic effects is lacking. In present study, the pharmacological and metabolomics studies were comparatively conducted between CH and CR in ovariectomized(OVX) female rats. Specifically, estrogen-like, anti-hyperlipidemia and anti-osteoporosis effects were evaluated through measuring serum biochemical parameters, histopathological examination and micro computed tomography(Micro-CT) scanning. At the same time, a gas chromatography-mass spectrometry(GC-MS)-based serum metabolomics method was employed to profile the metabolite compositional changes. As a result, both CR and CH displayed anti-osteoporosis and anti-hyperlipemia on menopause syndrome. Meanwhile, their potentials in improving the OVX-induced metabolic disorders were discovered. In conclusion, these results demonstrated that CH is therapeutically similar to CR in relieving menopausal symptoms and CH could be considered as a promising alternative to CR instead of an adulterant in the market of botanical dietary supplements.
文摘目的研究小儿升麻方对流感病毒性肺炎小鼠的治疗作用,并通过网络药理学方法探究其抗流感病毒性肺炎的作用机制。方法小鼠随机分为对照组,模型组,小儿升麻方低、中、高剂量(1.75、3.50、7.00g/kg)组和生理盐水组,给药第2天,经鼻滴入0.03 m L FM1流感病毒尿囊液建立流感病毒性肺炎模型,第7天测定小鼠肺指数。采用网络药理学方法在TCMIP数据库查找小儿升麻方各药材化学成分和靶点信息,在Genecards数据库中查找流感病毒性肺炎相关靶点,通过韦恩图筛选小儿升麻方与流感病毒性肺炎的共同靶点,借助Omicsbean分析系统与STRING数据库对共同靶点进行基因本体(gene ontology,GO)功能富集分析和京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)信号通路分析。结合STRING数据库与Cytoscape 3.7.0软件将共同靶点进行可视化处理,筛选核心靶点,构建"药材-成分-靶点-通路"网络。结果小儿升麻方高剂量组显著降低流感病毒性肺炎小鼠的肺指数(P<0.05)。小儿升麻方与流感病毒性肺炎有69个共同靶点,通过蛋白相互作用(protein-protein interaction,PPI)网络筛选出24个核心靶点,对应29个化学成分,86条主要通路。结论小儿升麻方对流感病毒性肺炎小鼠有潜在的治疗作用,可通过多成分、多靶点、多通路发挥治疗流感病毒性肺炎作用。
